Appraising Economic Evaluations in Emergency Medicine: High-Yield FRCEM SBA Practice Questions Explained

Economic evaluation has moved well beyond the walls of health policy departments. Every time a major ED adopts a high-sensitivity troponin pathway, funds point-of-care lactate testing, or debates whether CT-first or MRI-first imaging is justified for a given presentation, the underlying justification is, at least in part, economic. NICE technology appraisals determine which interventions reach NHS patients, and those appraisals turn on cost-effectiveness evidence. For candidates working through FRCEM SBA practice questions, this topic sits squarely within RCEM curriculum SLO 10 (research and evidence-based practice) and appears with reliable regularity in the exam, often in the form of a clinical vignette presenting a fictional trial alongside an economic model that must be interpreted or critiqued.

Why Health Economics Belongs in the Emergency Department

Emergency Medicine sits at the intersection of acute clinical need and system-level resource constraint. The NHS operates under explicit resource limits, and the opportunity cost of funding one intervention is the foregone benefit of another. This is not a theoretical construct: the decision to fund a novel thrombolytic, a point-of-care ultrasound programme, or a sepsis biomarker pathway involves real trade-offs that affect real patients. RCEM recognises this within its curriculum, embedding health economics literacy as a core competency for consultants.

For the trainee preparing FRCEM SBA exam questions, the practical implication is that questions in this domain are not asking you to perform calculations from scratch. They are asking whether you can read an economic evaluation critically, identify its design, interpret its outputs, and recognise methodological flaws. These are the same skills a consultant uses when reviewing a NICE technology appraisal before implementing a new pathway.

The Four Types of Economic Evaluation: Definitions and ED Relevance

All four types of economic evaluation share the same approach to measuring costs. They differ in how they quantify outcomes, and that distinction drives everything else.

Cost-Minimisation Analysis

Cost-minimisation analysis (CMA) assumes that two interventions produce identical outcomes and therefore compares only costs. It is appropriate in theory when equivalence has been rigorously demonstrated, for example in a high-quality randomised controlled trial showing two antihistamines produce statistically identical urticaria resolution rates. In practice, CMA is rarely valid because true equivalence is almost never established beyond doubt. Examiners frequently include CMA distractors in FRCEM SBA practice questions, precisely because candidates who have not considered its limitations will select it in inappropriate contexts.

Cost-Effectiveness Analysis

Cost-effectiveness analysis (CEA) expresses outcomes in natural clinical units relevant to the intervention: strokes prevented, patients correctly diagnosed with pulmonary embolism per protocol, or life-years gained. It is useful for comparing interventions within a single disease domain but cannot be used to compare across conditions. A CT pulmonary angiography pathway evaluated by cost per diagnosis made cannot be directly compared to an anaphylaxis protocol evaluated by cost per anaphylaxis death prevented. That cross-disease comparison requires a common currency, which is the QALY.

Cost-Utility Analysis

Cost-utility analysis (CUA) is the NICE reference case standard. Outcomes are expressed as quality-adjusted life-years, which combine length of life with a utility weight reflecting health-related quality of life (on a scale of 0, equivalent to death, to 1, equivalent to perfect health). The resulting ratio of incremental cost to incremental QALYs gained is the incremental cost-effectiveness ratio (ICER), expressed in pounds per QALY. This common currency allows NICE to compare a novel anticoagulant for atrial fibrillation against a biologic for inflammatory bowel disease, using a shared benchmark.

The NICE cost-effectiveness threshold sits between £20,000 and £30,000 per QALY. Interventions with an ICER below £20,000 per QALY are generally recommended. Those between £20,000 and £30,000 may be recommended with supporting evidence. Above £30,000, a strong and explicit justification is required. A small number of end-of-life treatments are assessed against a higher threshold. Understanding this threshold is a non-negotiable requirement for any candidate tackling FRCEM SBA exam questions in this topic area.

Cost-Benefit Analysis

Cost-benefit analysis (CBA) converts outcomes into monetary values using willingness-to-pay estimates. It is used in public health economics and government policy analysis but is rarely encountered in clinical technology appraisals. The ethical discomfort of placing an explicit monetary value on a human life is one reason it remains peripheral to clinical practice. Candidates should be able to identify CBA and articulate why it is not the NICE reference case standard.

A useful mnemonic is CUBE: Cost-minimisation assumes identical outcomes; Utility analysis uses QALYs (the NICE standard); Benefit analysis converts outcomes to monetary values; Effectiveness analysis uses natural clinical units.

Appraising the Structure of an Economic Model: The PEPTID Framework

Recognising the type of analysis is necessary but not sufficient. The examiner will also ask you to identify methodological weaknesses in a presented model. A structured appraisal framework ensures nothing is missed. PEPTID covers the six critical structural components:

• Perspective: Whose costs are counted? An NHS and personal social services perspective is the NICE reference case. A hospital-only perspective omits downstream community and social care costs and is a source of bias.
• Effectiveness data source: Is the effectiveness estimate drawn from a systematic review, a single trial, or expert opinion? Observational data and expert elicitation introduce bias and uncertainty that must be acknowledged.
• Population and comparator: Is the modelled population representative of the NHS ED population? Is the comparator the realistic alternative, or has a strawman comparator been chosen to favour the intervention? These are frequent exam pitfall scenarios.
• Time horizon: Is the time horizon long enough to capture all meaningful costs and consequences? A 30-day horizon for a pulmonary embolism pathway misses long-term anticoagulation costs and the downstream consequences of recurrent VTE. Conversely, an artificially long horizon amplifies uncertainty.
• Incremental analysis: Has the model reported the incremental cost and the incremental benefit (the differences between the intervention and comparator), rather than simply reporting average costs? Incremental analysis is mandatory for a valid economic evaluation.
• Discounting: Future costs and benefits are discounted to present values because a pound spent today has greater opportunity cost than a pound spent in five years. NICE reference case discounting rates are 3.5 percent per annum for both costs and health effects. Failure to discount in a model with a long time horizon is a methodological flaw.

Interpreting ICERs and the Cost-Effectiveness Plane

The ICER is the ratio of incremental cost to incremental QALYs gained. On the cost-effectiveness plane, the x-axis represents incremental health benefit and the y-axis represents incremental cost. Most novel interventions appear in the north-east quadrant: they cost more and produce more benefit than the comparator. Whether the intervention is cost-effective depends on whether the ICER falls below the willingness-to-pay threshold, represented as a line from the origin with a slope equal to the threshold value.

Interventions in the south-east quadrant are cost-saving and more effective: they are dominant and should always be recommended. Interventions in the north-west quadrant are more expensive and less effective: they are dominated and should never be recommended. These quadrant definitions are high-yield for MRCEM SBA and FRCEM SBA practice questions alike.

Sensitivity Analysis: Testing Robustness Under Uncertainty

No economic model is built on perfectly certain inputs. Drug prices fluctuate, utility weights are estimated from population surveys, and transition probabilities in Markov models are derived from trials that may not fully represent the NHS population. Sensitivity analysis quantifies how the ICER changes as inputs vary, and it is therefore central to the credibility of any economic conclusion.

One-way sensitivity analysis varies a single parameter across its plausible range while holding all others constant. It identifies which variables have the greatest influence on the ICER. A tornado diagram, listing variables in order of their impact on the ICER, is the standard presentation. If the ICER remains below the threshold even when a key input is varied to its most unfavourable plausible value, the conclusion is robust to that parameter.

Multi-way sensitivity analysis varies two or more parameters simultaneously. It is more realistic but harder to interpret because the number of possible combinations grows rapidly.

Probabilistic sensitivity analysis (PSA) is the NICE reference case standard. All uncertain parameters are assigned probability distributions and the model is run thousands of times using Monte Carlo simulation. The result is a cost-effectiveness acceptability curve (CEAC), which shows the probability that the intervention is cost-effective at any given willingness-to-pay threshold. A CEAC showing 70 percent probability of cost-effectiveness at £20,000 per QALY means that in 70 percent of simulated iterations, the ICER fell below that threshold.

Candidates who understand PSA and the CEAC are well positioned to answer the more sophisticated FRCEM SBA exam questions in this domain. The critical interpretive skill is recognising that high uncertainty, even around a favourable central ICER, may mean the decision to fund an intervention carries substantial risk of it not being cost-effective in practice.

Generalisability Challenges in Emergency Medicine

Emergency Medicine poses specific difficulties for cost-utility analysis that candidates must appreciate. The QALY is designed to capture changes in health-related quality of life over time. It performs well for chronic conditions where patients experience sustained gains or losses in utility over years. For the typical ED presentation, the relevant outcomes, whether a correct diagnosis, time to intervention, or avoidance of a discrete adverse event, occur over hours or days. The QALY instrument, often derived from EQ-5D questionnaires completed at weeks or months post-intervention, may not capture these short-term, high-stakes outcomes with sensitivity.

This does not make economic evaluation irrelevant in Emergency Medicine. High-sensitivity troponin pathways, for instance, have downstream cost and outcome consequences that extend far beyond the ED attendance. However, it does mean that candidates should scrutinise the outcome measure critically and consider whether the chosen metric genuinely reflects what clinicians and patients value in the ED context. This line of critical appraisal is exactly what BMJ health economics commentaries identify as a structural gap in ED economic evidence.

How the FRCEM SBA Exam Tests This Topic

Questions on economic evaluation within the FRCEM SBA exam typically take one of three forms. First, a definitional question: a vignette describes a study design and asks which type of economic evaluation has been conducted. The key discriminating feature is always the outcome measure. Second, an interpretive question: an ICER is presented alongside the NICE threshold and the candidate must decide whether the intervention should be recommended, and under what conditions. Third, a critical appraisal question: a model summary is presented with one or two embedded methodological flaws (for example, a hospital-only perspective, no discounting, or a comparator that is not the realistic alternative), and the candidate must identify the most significant weakness.

The RCEM curriculum maps this to SLO 10, which requires trainees to appraise research evidence critically and apply it to clinical practice. Economic evaluation is listed explicitly alongside clinical trial methodology and systematic review appraisal. Candidates who have worked through FRCEM SBA revision questions in this domain on a structured platform are better placed to distinguish the subtle between CMA and CEA, or between one-way and probabilistic sensitivity analysis, under exam conditions.

Revision Pearls: High-Yield Facts for FRCEM SBA Exam Questions

1. An economic evaluation requires both costs and outcomes. A cost analysis alone is not an economic evaluation.
2. The NICE reference case mandates cost-utility analysis using QALYs and probabilistic sensitivity analysis.
3. The NICE cost-effectiveness threshold is £20,000 to £30,000 per QALY. Memorise this range precisely.
4. South-east quadrant on the cost-effectiveness plane means dominant (more effective, less costly): always recommend. North-west means dominated (less effective, more costly): never recommend.
5. Discounting rate in the NICE reference case is 3.5 percent per annum for both costs and health effects.
6. Probabilistic sensitivity analysis is summarised by the cost-effectiveness acceptability curve, not a single ICER value.
7. QALYs are poorly suited to capturing short-term ED outcomes. This is a legitimate and examinable limitation of economic evaluations applied to Emergency Medicine.
8. The PEPTID mnemonic covers the six structural components of an economic model that must be appraised: Perspective, Effectiveness data, Population and comparator, Time horizon, Incremental analysis, Discounting.

Common Pitfalls: Where Candidates Lose Marks

• Confusing cost-effectiveness analysis (natural units) with cost-utility analysis (QALYs). These are not interchangeable in an exam answer.
• Selecting cost-minimisation analysis without checking whether genuine equivalence has been established. The assumption of identical outcomes must be justified, not assumed.
• Interpreting a favourable central ICER as a definitive recommendation without considering the uncertainty shown in the sensitivity analysis.
• Forgetting that the NICE perspective includes both NHS costs and personal social services costs. Hospital-only perspective is a methodological weakness, not a valid simplification.
• Failing to note the time horizon relative to the natural history of the condition. A short time horizon for a condition with long-term consequences will underestimate both costs and benefits, potentially in a direction that flatters the intervention.
• Treating a cost-benefit analysis as equivalent to a cost-utility analysis because both produce a ratio. The outputs and the policy relevance are fundamentally different.

How EM Learning Centre Supports Your FRCEM Single Best Answer Revision

Mastering health economics for the exam requires more than reading a definition table. It requires worked questions that place these concepts in realistic clinical vignettes, with detailed explanations that unpick the reasoning behind each answer option. The FRCEM Single Best Answer revision course at EM Learning Centre includes structured teaching on research and evidence-based practice, covering economic evaluation alongside trial methodology, systematic review appraisal, and statistical interpretation. Each lesson is mapped directly to the RCEM curriculum, so you can be confident your revision aligns with what the examiners are actually testing.

Whether you are working through FRCEM SBA practice questions in a focused revision block or building foundational knowledge across the curriculum, the platform provides the depth and clinical context that generic question banks cannot replicate. The lessons referenced in this post, including those on acute allergy, anaphylactoid reactions, angioedema, hereditary angioedema, and urticaria, illustrate how economic thinking applies to common ED presentations where pathway design and resource allocation intersect directly with patient outcomes. Visit the EM Learning Centre homepage to explore the full FRCEM Single Best Answer course and begin a revision programme that treats you as the clinician you are becoming.

References

1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. NICE, London. nice.org.uk
2. Royal College of Emergency Medicine. RCEM Curriculum and Assessment. RCEM, London. rcem.ac.uk
3. Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press, 2015. Summarised via BMJ
4. National Institute for Health and Care Excellence. Cost-effectiveness and NICE threshold guidance. nice.org.uk
5. NHS England. Value-based healthcare and resource allocation frameworks. nhs.uk